Morgan Stanley
ELAB icon

Morgan Stanley’s Elevai Labs ELAB Stock Holding History

Morgan Stanley’s Portfolio ELAB Stock Details ELAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$64.1K Buy
5,300
+3,800
+253% +$96.2K ﹤0.01% 6416
2026
Q1 		$89.8K Buy
+1,500
New +$192K ﹤0.01% 6213

Other funds holding ELAB

Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Morgan Stanley's ELAB Position: Q2 2026 in Review

Morgan Stanley increased its Elevai Labs (ELAB) stake by 253% in Q2 2026, buying an estimated $96.2K and bringing the position to 5,300 shares worth $64.1K. The position accounts for ﹤0.01% of the portfolio, ranked #6416.

Morgan Stanley first reported a position in ELAB in Q1 2026 and has held it in 2 quarters since. The position peaked at $89.8K in Q1 2026. 11 funds tracked by Wall St. Rank hold ELAB as of Q2 2026.

  • Morgan Stanley held 5,300 shares of Elevai Labs worth $64.1K as of Q2 2026.
  • Morgan Stanley bought 3,800 Elevai Labs shares in Q2 2026, an estimated $96.2K.
  • Elevai Labs made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #6416 holding.
  • Morgan Stanley first reported a position in Elevai Labs in Q1 2026 and has held it in 2 quarters since.
  • Morgan Stanley's Elevai Labs position peaked at $89.8K in Q1 2026.
  • 11 funds tracked by Wall St. Rank held Elevai Labs as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.